Protalix BioTherapeutics Inc.

Protalix BioTherapeutics Inc.

PLX

Get informed when a big investor buys or sells

+ Follow
Market Cap$190.95M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Protalix BioTherapeutics Inc.Protalix BioTherapeutics Inc.12.3-23%-0.1
$-2.48

Current Fair Value

204.6% downside

Overvalued by 204.6% based on the discounted cash flow analysis.

Share Statistics

Market cap$190.95 Million
Enterprise Value$157.72 Million
Dividend Yield$- (-)
Earnings per Share$-0.08
Beta0
Outstanding Shares79,848,892

Return

Return on Equity22.81%ROE
Return on Assets14.98%
Return on Invested Capital20.33%

Valuation & Multiples

P/E Ratio12.27P/E Ratio
PEG-2.02PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue2.06
Enterprise Value to EBIT10.35
Enterprise Value to Net Income10
Total Debt to Enterprise0.05
Debt to Equity0.13Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 13, 2026
EPS Estimate
$-0.01
Average shareholder expectation
Revenue Estimate
$11.50 M
Average shareholder expectation

Next Earnings Call

Expected Date
August 13, 2026
EPS Estimate
$-0.01
Average shareholder expectation
Revenue Estimate
$12.95 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.5186▼ 110.49%
Total Calls260,500▲ 1432.35%
Total Puts135,100▲ 389.49%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %21.12%▲ 2.14%
Total Invested$36.57M▲ 36.30%
Investors Holding106▲ 22.00%

ESG Score

No data

About Protalix BioTherapeutics Inc.

CEO: Dror Bashan